Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $107.70 million. The enterprise value is $171.80 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 234.70 million shares outstanding. The number of shares has increased by 1.01% in one year.
| Current Share Class | 234.70M |
| Shares Outstanding | 234.70M |
| Shares Change (YoY) | +1.01% |
| Shares Change (QoQ) | -0.60% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 67.17% |
| Float | 211.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.18 |
| Forward PS | 6.21 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64
| Current Ratio | 2.64 |
| Quick Ratio | 2.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -41.86% |
| Return on Invested Capital (ROIC) | -65.30% |
| Return on Capital Employed (ROCE) | -150.03% |
| Weighted Average Cost of Capital (WACC) | 8.34% |
| Revenue Per Employee | $299,204 |
| Profits Per Employee | -$1.05M |
| Employee Count | 162 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.53% in the last 52 weeks. The beta is 2.16, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.16 |
| 52-Week Price Change | -44.53% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 41.82 |
| Average Volume (20 Days) | 11,803,566 |
Short Selling Information
The latest short interest is 37.50 million, so 15.98% of the outstanding shares have been sold short.
| Short Interest | 37.50M |
| Short Previous Month | 36.62M |
| Short % of Shares Out | 15.98% |
| Short % of Float | 17.76% |
| Short Ratio (days to cover) | 1.14 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $48.47 million and -$170.37 million in losses. Loss per share was -$0.75.
| Revenue | 48.47M |
| Gross Profit | 48.47M |
| Operating Income | -163.25M |
| Pretax Income | -170.46M |
| Net Income | -170.37M |
| EBITDA | -163.23M |
| EBIT | -163.25M |
| Loss Per Share | -$0.75 |
Full Income StatementBalance Sheet
The company has $136.93 million in cash and $202.91 million in debt, with a net cash position of -$65.97 million or -$0.28 per share.
| Cash & Cash Equivalents | 136.93M |
| Total Debt | 202.91M |
| Net Cash | -65.97M |
| Net Cash Per Share | -$0.28 |
| Equity (Book Value) | -122.76M |
| Book Value Per Share | -0.53 |
| Working Capital | 104.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$171.27 million and capital expenditures -$79,000, giving a free cash flow of -$171.35 million.
| Operating Cash Flow | -171.27M |
| Capital Expenditures | -79,000 |
| Depreciation & Amortization | 24,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -171.35M |
| FCF Per Share | -$0.73 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -336.81% |
| Pretax Margin | -351.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.01% |
| Shareholder Yield | -1.01% |
| Earnings Yield | -160.99% |
| FCF Yield | -161.91% |
Analyst Forecast
The average price target for Gossamer Bio is $4.19, which is 813.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.19 |
| Price Target Difference | 813.05% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 71.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -12.96. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.96 |
| Piotroski F-Score | n/a |
